A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Stopped early · Phase 1

Conditions studied: Advanced Solid Tumors, Metastatic Solid Tumors

In brief

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.

Key facts

Study ID

NCT03854227

Run by

Pfizer

People needed

54

Starts

2019-03-14

Expected to finish

2022-04-27

Last updated by the study team

2025-01-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed locally advanced or metastatic NSCLC, urothelial carcinoma or HNSCC
• Progressed after at least 1 line of treatment and no more than 3 lines of treatment
• At least one measurable lesion as defined by RECIST version 1.1
• ECOG Performance Status 0 or 1
• Adequate Bone Marrow Function
• Adequate Renal Function
• Adequate Liver Function
• Resolved acute effects of any prior therapy

You may not qualify if…

• Known active uncontrolled or symptomatic CNS metastases.
• Major surgery, radiation therapy, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry.
• Active, uncontrolled infection, including COVID-19
• Known or suspected hypersensitivity to PF-06939999
• Inability to consume or absorb study drug

Where it is running

• Scottsdale Healthcare Hospitals d/b/a HonorHealth — Scottsdale, Arizona, United States
• Virginia G. Piper Cancer Pharmacy — Scottsdale, Arizona, United States
• Keck Hospital of USC — Los Angeles, California, United States
• LAC + USC Medical Center — Los Angeles, California, United States
• USC Norris Comprehensive Cancer Center — Los Angeles, California, United States
• USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Keck Medical Center of USC Pasadena — Pasadena, California, United States
• AdventHealth Celebration Infusion Center — Celebration, Florida, United States
• AdventHealth Medical Group Oncology Research at Celebration — Celebration, Florida, United States
• University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• AdventHealth Orlando - Investigational Drug Services — Orlando, Florida, United States
• AdventHealth Orlando Infusion Center — Orlando, Florida, United States
• AdventHealth Orlando — Orlando, Florida, United States
• St. Joseph Mercy Hospital — Ann Arbor, Michigan, United States
• St. Joseph Mercy Brighton — Brighton, Michigan, United States
• Henry-Joyce Cancer Clinic — Nashville, Tennessee, United States
• Oncology IDS Pharmacy — Nashville, Tennessee, United States
• The University of Texas — Houston, Texas, United States
• NEXT Oncology — San Antonio, Texas, United States
• Inova Schar Cancer Institute — Fairfax, Virginia, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States
• University of Washington Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.